Midazolam nasal spray
میدازولام اسپری بینی
🧠 Nervous SystemBenzodiazepine (rescue anticonvulsant)
Market / country: 🇺🇸 USA
Nayzilam (US)
🧮 Dose calculator
Status epilepticus / acute repetitive seizures · Regimen source: FDA Nayzilam · 2.2
- • If no response after 10 min, one more spray in the other nostril. No more than 2 doses per cluster; no more than one cluster every 3 days and 5 per month. FDA Nayzilam · 2.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to midazolam; acute narrow-angle glaucoma. FDA Nayzilam · 4
- ⛔ Not labelled under 12 years. FDA Nayzilam · 8.4
Warnings
- • Boxed warning: with opioids respiratory depression and death; abuse and dependence. FDA Nayzilam · Boxed Warning
Formulations
- 5 mg/0.1 mL single-dose nasal spray — nasal spray 🇺🇸 USA FDA Nayzilam · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Nayzilam · 8.1
“Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see Warnings and Precautions (5.9) and Clinical Considerations ].”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Nayzilam · 8.2
“Risk Summary Midazolam is excreted in human milk.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Nayzilam · 8.4
“Safety and effectiveness in pediatric patients below the age of 12 years have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Nayzilam · 8.5
“… ciated with rare reports of death under circumstances compatible with cardiorespiratory depression [see Warnings and Precautions (5.4) ].”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA211321
- DailyMed (FDA label)FDA Nayzilam
- MedlinePlus (NIH)Midazolam Nasal Spray
- WHO ATC/DDDN05CD08
- Darooyab (Iran)Midazolam
🇮🇷 Registered in Iran Darooyab · G-1307/Midazolam
Dosage forms with Iranian generic codes, per Darooyab.
- 17001 · MIDAZOLAM 2.5MG/ML 100ML SYRUP · شربت میدازولام ۲٫۵ میلیگرم / میلیلیتر ۱۰۰ میلیلیتر
- 01591 · MIDAZOLAM HCL 15MG/3ML AMP · آمپول میدازولام هیدروکلراید ۱۵ میلیگرم / ۳ میلیلیتر
- 02010 · MIDAZOLAM HCL 2MG/ML SYRUP · شربت میدازولام هیدروکلراید ۲ میلیگرم / میلیلیتر
- 00852 · MIDAZOLAM HCL 5MG/1ML AMP · آمپول میدازولام هیدروکلراید ۵ میلیگرم / ۱ میلیلیتر
- 17231 · MIDAZOLAM MALEATE 50MG/5ML BUCCAL LIQUID · مایع میدازولام مالئات ۵۰ میلیگرم / ۵ میلیلیتر بوککال
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Nayzilam · 3FDA Nayzilam · 2.2FDA Nayzilam · 4FDA Nayzilam · 8.4FDA Nayzilam · Boxed WarningFDA Nayzilam · 8.1FDA Nayzilam · 8.2FDA Nayzilam · 8.5FDA Nayzilam · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1307/Midazolam
- Clinical review⚠ Unverified